Camber Pharmaceuticals – Recall of losartan
February 28, 2019 - The FDA announced the voluntary, consumer-level recall of several lots of Camber Pharmaceuticals’ losartan tablets due to the detection of trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA), a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs.
Top